Curanex Pharmaceuticals Inc CURX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-08-26 |
| Shares Out. | 28,360,000 |
| Website | curanexpharma.com/ ↗ |
| Phone | 17186736078 |
| Employees | 6 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$3.3M |
| Free Cash Flow | -$12.1M |
| Total Assets | $5.1M |
| Total Liabilities | $286,254 |
| Equity | $4.8M |
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Curanex Pharmaceuticals Inc is a publicly traded company under the ticker symbol CURX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.